Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Phase III study of leniolisib in patients with activated PI3K delta syndrome

V. Koneti Rao, MD, FRCPA, National Institute of Allergy and Infectious Diseases, Bethesda, MD, shares some results from a Phase III study evaluating the use of leniolisib, a delta PI3K inhibitor, in patients with activated PI3K delta syndrome (APDS/PASLI). Dr Rao first provides some detailed information on symptoms and clinical manifestations of this rare disease, and then goes on to discuss the efficacy of leniolisib in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.